Blog

Alumni Profiles Series: Vernon Chun Jiang

 November 4, 2026

Dr. Vernon Chun Jiang is a senior pharmaceutical executive with more than 30 years of experience in drug research, development, and commercialization. Based in the San Francisco Bay Area, he has led process chemistry and formulation development for several marketed antibiotics, including Teflaro® (ceftaroline fosamil), Dalvance® (dalbavancin), and Zerbaxa® (ceftolozane/tazobactam). He began his industry career at Roche, where he received extensive training and advanced through positions of increasing responsibility in chemistry, manufacturing, and controls. Throughout his career, Dr. Jiang has been a founding team member or co-founder of several venture-backed biotechnology companies, including Calixa Therapeutics (acquired by Cubist/Merck), Kalidex Pharmaceuticals, Nexcida/Recida Therapeutics, K-Gen, Inc. (acquired by BridgeBio), and Cothera Bioscience, where he currently serves as co-founder, chief technology officer, and executive vice president, leading product development and clinical trials. He also advises leading U.S. venture capital firms. Dr. Jiang earned his Ph.D. in chemistry from Duke University and his B.S. in polymer chemistry from the University of Science and Technology of China. Find his profile on the Duke Alumni Network (login required).

What first drew you to Duke, and what did your graduate research focus on?

As an undergraduate, I studied polymer chemistry and became fascinated by how subtle differences in polymer composition could dramatically change a material's properties. At the time, most separation methods focused on molecular size rather than chemical composition. Professor Charles Lochmüller had recently developed a new high-performance liquid chromatography (HPLC) method for separating polymers, and I was intrigued by the possibilities. That curiosity led me to Duke, where I joined his research group.

My Ph.D. research focused on developing reversed-phase HPLC methods that used temperature as a key variable for polymer separation. Although it was fundamental research, it also had important practical applications. The work proved to be ahead of its time and became highly relevant as polyethylene glycol (PEG), one of the polymers I studied, emerged as a key material for drug delivery systems. Today, the principles we developed are widely used in industry to separate polymers based on compositions and end-groups. By controlling temperature, researchers and manufacturers can achieve highly efficient separations, even on large-scale columns, making the approach valuable for both research and commercial production.

As you were finishing your Ph.D., what career path did you envision for yourself?

Like many graduate students, I wasn't entirely sure whether I wanted to pursue academia or industry. My research had applications in both, so I sought advice from my mentor. His recommendation was simple: try both if you can, make a thoughtful decision, and don't stay in one place too long if you realize it isn't the right fit.

After graduation, I was offered a generous National Research Council postdoctoral fellowship and a couple of industry opportunities. Ultimately, I chose to join Roche because I was excited by the opportunity to conduct rigorous basic research with direct applications in pharmaceutical development. At Roche, I received exceptional training, not only in chemistry, but also in the highly regulated process of developing medicines for patients. That experience gave me a deep appreciation for how scientific discoveries are transformed into real therapies that improve lives.

Your career has taken you from large pharmaceutical companies to founding multiple biotechnology startups. What motivated those transitions?

Graduate school teaches you much more than a specific area of science. It teaches you how to solve problems, think critically, and persist through uncertainty. Those skills have been the foundation of every stage of my career.

At Roche, I expanded beyond polymer chemistry into small-molecule drug development and gained a broader understanding of how drug discovery, manufacturing, and commercialization fit together. As my responsibilities grew, I intentionally sought opportunities that would broaden my experience. My goal was to become more of a generalist so I could lead larger teams, eventually head an entire department, and ultimately build and lead companies.

That mindset led me into biotechnology startups. Working in smaller companies gave me the opportunity to build organizations from the ground up, lead multidisciplinary teams, raise venture capital, and help advance promising therapies from early development into the clinic. Every new role required me to learn an entirely new set of skills, and that's what made the journey so rewarding.

Never be afraid of taking on responsibilities that seem bigger than your current experience. Those opportunities often become the moments when you grow the most.

Image
“Never be afraid of taking on responsibilities that seem bigger than your current experience. Those opportunities often become the moments when you grow the most.”

You've spent decades developing new medicines. Is there a moment that captures what drug development is really like?

Drug development is full of moments where the solution isn't obvious.

I remember one manufacturing run where static electricity prevented a powdered drug from properly filling sterile vials. It was the middle of the night, everyone was exhausted, and we were working under significant budget and timeline pressures. If we lost that batch, we could have delayed the clinical program by a year or more.

Instead of rushing to force a solution, we stopped. We preserved the material, stepped back, and carefully evaluated our options. That decision ultimately saved the project. Looking back, what I'm most proud of isn't that we solved the problem; it's that we relied on good science, stayed calm under pressure, and trusted the process. Today, that drug has successfully reached patients with hospital-acquired drug-resistant infections.

Experiences like that remind me that some of the most difficult challenges become the most rewarding once you find a solution.

What advice would you offer current Duke graduate students preparing for their own careers?

Take advantage of everything Duke has to offer, not just your research.

If I could do graduate school again, I would spend even more time exploring courses outside my discipline, attending seminars, learning about entrepreneurship, intellectual property, and business, and meeting people from different fields. Graduate school is one of the few times in your career when you have access to so many opportunities in one place.

I also encourage students to think broadly about their careers. Have a blueprint for where you want to go but stay adaptable. The pharmaceutical industry is changing rapidly with advances in artificial intelligence, automation, and new business models. Traditional career paths are no longer the only option. Startups, consulting, venture capital, and many other fields all value the skills developed during a Ph.D.

Finally, build your professional network early. Attend conferences, introduce yourself to people, and stay connected. Every major opportunity in my career has come through relationships I built over time. Science is important, but the people you meet along the way often become your collaborators, mentors, and advocates for years to come.


AUTHOR

Image
Sarah Angle headshot
Sarah Angle

Ph.D. candidate, Chemistry

Sarah Angle is a fourth-year Ph.D. candidate in the Chemistry Department. Her research focuses on the design of antibacterial prodrugs to selectively target pathogenic bacteria. Originally from Virginia, she earned her B.S. from Virginia Tech, where she discovered her passion for research. Outside of the lab, she enjoys running, spending time with her family, and being outdoors with her dogs.